Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

3 million, or $0.01 per diluted share, for the prior year period.

For the six months ended June 30, 2011, net income attributable to common shareholders was $2.9 million, or $0.14 per diluted share, compared with $0.6 million, or $0.03 per diluted share, for the same period in 2010.

Balance Sheet:  As of June 30, 2011, cash and cash equivalents grew to $69.8 million, compared to $66.0 million at March 31, 2011, due to strong operating cash flow during the quarter. Total assets at June 30, 2011, grew to $94.6 million. Cumberland's total debt as of June 30, 2011, was $5.8 million, including a current portion of $4.0 million, compared to $6.5 million in total debt at March 31, 2011. Following the end of the quarter, the Company repaid its term loan in full. Cumberland also increased its revolving line of credit to $10 million, which is expandable to $20 million and incorporated reduced pricing terms.

"We are very pleased with the Company's performance during the second quarter, having accomplished several key objectives for the year and delivering strong growth in revenue, income and cash flow," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our team's execution of the launch of the new Acetadote formulation, the addition of a key pipeline candidate and growth in our network of international commercial partners are a few highlights from the quarter.  From a historical performance perspective, this quarter also trends nicely with our consistent quarter-over-quarter growth in net revenue, EBITDA, operating income and net income."

Based on its second quarter performance, Cumberland is raising its full year 2011 revenue guidance to $51 - $55 million. This guidance represents the Company's best estimate of future results, which may be affected by factors described below in "Forward-Looking Statements."

Company HighlightsAcetadote®

New Formulation

In January 2011, t
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... Oct. 30, 2014  The number of retail health ... is growing steadily, thanks to drug store chains, according ... of the economic downturn, retail clinic growth had been ... opportunities, as the number of retail clinics reached nearly ... Retail Clinics Market Overview and 2014 Consumer Survey Results ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3
... TECH ) financial results for the quarter ended September ... earnings were $27.5 million or $.74 per diluted share.  Adjusted ... $.81 per diluted share after adjustment for intangible asset amortization ... written-up to fair value as part of acquisitions completed in ...
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Nervous System Disorders Therapeutics Market to ... Disorder and Schizophrenia Accounted for Half ...
Cached Medicine Technology:Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 2Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 3Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 4Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 5Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 6Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 7Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... 30, 2014 USARAD Holdings ... teleradiology and specialty telemedicine solutions provider, including ... its existing teleradiology services at Mission Bend ER, ... expert telemedicine services, to the state-of-the-art, 24/7, freestanding ... result of this innovative partnership, there will be ...
(Date:10/30/2014)... Carolina (PRWEB) October 30, 2014 The ... should be more vigorously exercised to help maintain better ... authored the book ‘Dementia Express: Lose Your Memory in ... uses counterintuitive reasoning and sometimes conflicting attitudes to help ... for the mind, a reader must decipher the hidden ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3
... is one step in a long, slow process of reproductive ... age 40 and declining levels of the hormones estrogen and ... a female., ,Menopause, or the “change of life,” affects ... help women cope up better with menopause, hormone replacement therapy ...
... declared Tuberculosis as an emergency in Africa. It is ... WHO Regional // Committee for Africa comprising health ministers ... in the African region. The deaths have quadrupled in ... adopted today at the end of the Committee's fifty-fifth ...
... expression responsible for extreme farsightedness in people. , ... rare, potentially blinding disorder, is caused // by an ... eye growth and regulates the organ's shape and focus. ... the journal Proceedings of the National Academy of Sciences., ...
... probe for the treatment of brain cancer is the ... of Neurological Disorders at Manipal Hospital in Bangalore. // ... ,Removal of brain tumors surgically leads to enormous ... depends on the surgeon’s skill. By using the new ...
... a report published in the September issue of the ... programs that advocate quick and short working out sessions ... health conditions that can lead to diseases. To prevent ... and strenuous workout sessions are required every week. ...
... shown that use of general anesthesia for heroin detoxification ... detoxification. The study, which came in the latest issue ... // of general anesthesia in these circumstances can also ... heroin withdrawal remains plagued by patient discomfort and high ...
Cached Medicine News:Health News:WHO declares Tuberculosis – ‘An Emergency’ in Afr 2Health News:Genetic Cause For Farsightedness Discovered 2Health News:Radio-guided Neurosurgery for treatment of Brain cancer 2Health News:General Anesthesia For Heroin Detoxification Is No Good 2
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: